ACHV Quote, Financials, Valuation and Earnings

Electromed has a net margin of -- compared to Achieve Life Sciences's net margin of 12.11%. Achieve Life Sciences's return on equity of -- beat Electromed's return on equity of 15.91%.

Achieve Life Sciences has a consensus price target of $16.00, signalling upside risk potential of 566.67%. On the other hand Electromed has an analysts' consensus of $37.00 which suggests that it could grow by 62.21%. Given that Achieve Life Sciences has higher upside potential than Electromed, analysts believe Achieve Life Sciences is more attractive than Electromed.

Achieve Life Sciences has a beta of 1.587, which suggesting that the stock is 58.675% more volatile than S&P 500. In comparison Electromed has a beta of 0.594, suggesting its less volatile than the S&P 500 by 40.575%.

Achieve Life Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Achieve Life Sciences pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

Achieve Life Sciences quarterly revenues are --, which are smaller than Electromed quarterly revenues of $16.3M. Achieve Life Sciences's net income of -$12.4M is lower than Electromed's net income of $2M. Notably, Achieve Life Sciences's price-to-earnings ratio is -- while Electromed's PE ratio is 30.41x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Achieve Life Sciences is -- versus 3.43x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

Nuwellis has a net margin of -- compared to Achieve Life Sciences's net margin of -63.22%. Achieve Life Sciences's return on equity of -- beat Nuwellis's return on equity of -800.59%.

Achieve Life Sciences has a consensus price target of $16.00, signalling upside risk potential of 566.67%. On the other hand Nuwellis has an analysts' consensus of $13.00 which suggests that it could grow by 1392.54%. Given that Nuwellis has higher upside potential than Achieve Life Sciences, analysts believe Nuwellis is more attractive than Achieve Life Sciences.

Achieve Life Sciences has a beta of 1.587, which suggesting that the stock is 58.675% more volatile than S&P 500. In comparison Nuwellis has a beta of 0.510, suggesting its less volatile than the S&P 500 by 49.013%.

Achieve Life Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nuwellis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Achieve Life Sciences pays -- of its earnings as a dividend. Nuwellis pays out -- of its earnings as a dividend.

Achieve Life Sciences quarterly revenues are --, which are smaller than Nuwellis quarterly revenues of $2.3M. Achieve Life Sciences's net income of -$12.4M is lower than Nuwellis's net income of -$1.5M. Notably, Achieve Life Sciences's price-to-earnings ratio is -- while Nuwellis's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Achieve Life Sciences is -- versus 0.16x for Nuwellis. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX has a net margin of -- compared to Achieve Life Sciences's net margin of -1226.82%. Achieve Life Sciences's return on equity of -- beat VolitionRX's return on equity of --.

Achieve Life Sciences has a consensus price target of $16.00, signalling upside risk potential of 566.67%. On the other hand VolitionRX has an analysts' consensus of $2.92 which suggests that it could grow by 509.17%. Given that Achieve Life Sciences has higher upside potential than VolitionRX, analysts believe Achieve Life Sciences is more attractive than VolitionRX.

Achieve Life Sciences has a beta of 1.587, which suggesting that the stock is 58.675% more volatile than S&P 500. In comparison VolitionRX has a beta of 1.155, suggesting its more volatile than the S&P 500 by 15.463%.

Achieve Life Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Achieve Life Sciences pays -- of its earnings as a dividend. VolitionRX pays out -- of its earnings as a dividend.

Achieve Life Sciences quarterly revenues are --, which are smaller than VolitionRX quarterly revenues of $474.5K. Achieve Life Sciences's net income of -$12.4M is lower than VolitionRX's net income of -$5.8M. Notably, Achieve Life Sciences's price-to-earnings ratio is -- while VolitionRX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Achieve Life Sciences is -- versus 33.67x for VolitionRX. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -- compared to Achieve Life Sciences's net margin of -10.04%. Achieve Life Sciences's return on equity of -- beat Xtant Medical Holdings's return on equity of -35.34%.

Achieve Life Sciences has a consensus price target of $16.00, signalling upside risk potential of 566.67%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 292.38%. Given that Achieve Life Sciences has higher upside potential than Xtant Medical Holdings, analysts believe Achieve Life Sciences is more attractive than Xtant Medical Holdings.

Achieve Life Sciences has a beta of 1.587, which suggesting that the stock is 58.675% more volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of -0.033, suggesting its less volatile than the S&P 500 by 103.341%.

Achieve Life Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Achieve Life Sciences pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

Achieve Life Sciences quarterly revenues are --, which are smaller than Xtant Medical Holdings quarterly revenues of $31.5M. Achieve Life Sciences's net income of -$12.4M is lower than Xtant Medical Holdings's net income of -$3.2M. Notably, Achieve Life Sciences's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Achieve Life Sciences is -- versus 0.51x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.